Juan Posada
Hematology & Oncology · Temple, TXNPI 1508827361
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,052 of the $1,680 with a category attached, or 62.6%. 18 manufacturers reported payments, led by Merck at 53.9% of the total. Reporting peaked in 2019 at $985 and has fallen 73.1% since, to $265 in 2023. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 55 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$906
- Johnson & Johnson$245
- AstraZeneca$98
- Novartis$57
- Bristol Myers Squibb$51
- Astellas Pharma US Inc$42
- plus $282 from 12 others
Across 141 payments — averaging $4708.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$630K
- Exelixis Inc.$19K
- Bristol Myers Squibb$8K
- Aptevo Therapeutics Inc$7K
What the payments were for
- Travel & lodging$62837%
- Food & beverage$1,05263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $906 |
| Johnson & Johnson(2 entities) | 12 | $245 |
| AstraZeneca | 5 | $98 |
| Novartis | 3 | $57 |
| Bristol Myers Squibb | 3 | $51 |
| Astellas Pharma US Inc | 2 | $42 |
| Incyte Corporation | 2 | $41 |
| Eisai Inc. | 2 | $34 |
| AbbVie | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Sanofi | 2 | $30 |
| Pfizer | 1 | $17 |
| Amgen | 1 | $17 |
| Dova Pharmaceuticals | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Exelixis Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$529
How this compares
$1,680 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Temple
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.